Zurcher Kantonalbank Zurich Cantonalbank Has $954,000 Holdings in Insmed Incorporated (NASDAQ:INSM)

Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Insmed Incorporated (NASDAQ:INSM) by 7.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 30,772 shares of the biopharmaceutical company’s stock after buying an additional 2,095 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Insmed were worth $954,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Assetmark Inc. increased its position in shares of Insmed by 10.7% in the third quarter. Assetmark Inc. now owns 4,799 shares of the biopharmaceutical company’s stock valued at $121,000 after acquiring an additional 463 shares during the last quarter. Arizona State Retirement System grew its holdings in Insmed by 1.4% during the third quarter. Arizona State Retirement System now owns 38,846 shares of the biopharmaceutical company’s stock worth $981,000 after purchasing an additional 526 shares during the period. International Assets Investment Management LLC bought a new position in Insmed during the fourth quarter worth about $25,000. Diversified Trust Co grew its holdings in Insmed by 4.2% during the third quarter. Diversified Trust Co now owns 19,634 shares of the biopharmaceutical company’s stock worth $496,000 after purchasing an additional 792 shares during the period. Finally, Victory Capital Management Inc. grew its holdings in Insmed by 6.5% during the third quarter. Victory Capital Management Inc. now owns 15,486 shares of the biopharmaceutical company’s stock worth $391,000 after purchasing an additional 948 shares during the period.

Insmed Trading Down 0.5 %

NASDAQ INSM opened at $24.80 on Monday. Insmed Incorporated has a 1-year low of $18.08 and a 1-year high of $32.00. The company has a 50 day moving average of $27.07 and a 200-day moving average of $27.06. The company has a market cap of $3.68 billion, a price-to-earnings ratio of -4.64 and a beta of 0.92.

Insmed (NASDAQ:INSM) last released its quarterly earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($1.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.13) by ($0.15). The firm had revenue of $83.70 million for the quarter, compared to the consensus estimate of $82.15 million. During the same period last year, the firm posted ($1.20) EPS. The company’s quarterly revenue was up 41.1% compared to the same quarter last year. On average, equities research analysts forecast that Insmed Incorporated will post -4.65 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on INSM. Truist Financial began coverage on Insmed in a report on Tuesday, April 23rd. They set a “buy” rating and a $48.00 price target for the company. Wells Fargo & Company reiterated an “overweight” rating and set a $55.00 price target on shares of Insmed in a report on Monday, April 1st. Barclays lifted their price target on Insmed from $37.00 to $40.00 and gave the stock an “overweight” rating in a report on Thursday, April 11th. UBS Group assumed coverage on Insmed in a report on Tuesday, February 27th. They set a “buy” rating and a $46.00 price target for the company. Finally, Guggenheim boosted their price objective on Insmed from $52.00 to $54.00 and gave the stock a “buy” rating in a report on Tuesday, February 27th. One equities research analyst has rated the stock with a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $44.92.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.